trial summary · NCT06863402
Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype
Nemtabrutinib and Pembrolizumab in Patients With Richter Transformation: A Phase II Study
Trial record from the TrialBase DB dataset, status RECRUITING, condition Richter Syndrome, sponsored by Roswell Park Cancer Institute. Facts below are exported values from the current release, not inferred or edited prose.
Summary
The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.
This phase II trial tests how well nemtabrutinib in combination with pembrolizumab works in treating patients with Richter transformation, diffuse large B-cell lymphoma subtype (RT-DLBCL). Nemtabrutinib is in a class of medications called kinase inhibitors. It blocks a protein called BTK, which is present on B-cells (a type of white blood cell) in cancers such as Richter transformation at abnormal levels. This may help keep cancer cells from growing and spreading. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of cancer cells to grow and spread. Giving nemtabrutinib in combination with pembrolizumab may kill more cancer cells in patients with RT-DLBCL.
Source record: https://clinicaltrials.gov/study/NCT06863402
Facts
| registry id | NCT06863402 |
|---|---|
| primary registry | clinicaltrials-gov |
| recruitment status | RECRUITING |
| phase | PHASE2 |
| study type | INTERVENTIONAL |
| lead condition | Richter Syndrome |
| sponsor | Roswell Park Cancer Institute |
| sponsor class | OTHER |
| enrollment | 32 |
| start date | 2026-11-15 |
| primary completion | 2029-06-01 |
| completion | 2030-06-01 |
| results posted | not reported |
Conditions
- Richter Syndrome
- Diffuse Large B-Cell Lymphoma
- Chronic Lymphocytic Leukemia
Interventions
- Biospecimen Collection
- Bone Marrow Biopsy
- Computed Tomography
- Echocardiography
- Multigated Acquisition Scan
- Nemtabrutinib
- Pembrolizumab
- Positron Emission Tomography
- Questionnaire Administration
Countries
- United States
Intervention types: BIOLOGICAL, DRUG, OTHER, PROCEDURE
Work with this record
- Field definitions
Types, scope, and provenance rules for every exported field.
- REST API
Query the same gate-backed records programmatically.
- Evaluation sample
Download a bounded slice before buying.
- $29 API Pass
Seven days of REST and MCP access; credited toward the licence.